메뉴 건너뛰기




Volumn 65, Issue 4, 2012, Pages 430-436

Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?

Author keywords

Abnormal lipoprotein metabolism; Diabetic nephropathy; Dyslipidemia; PPAR agonists; Renal dysfunction

Indexed keywords

FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PLACEBO;

EID: 84858339432     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2012.01.004     Document Type: Review
Times cited : (53)

References (83)
  • 1
    • 84925947100 scopus 로고    scopus 로고
    • Obesity, metabolic syndrome and diabetic nephropathy
    • C. Maric, and J.E. Hall Obesity, metabolic syndrome and diabetic nephropathy Contrib Nephrol 170 2011 28 35
    • (2011) Contrib Nephrol , vol.170 , pp. 28-35
    • Maric, C.1    Hall, J.E.2
  • 2
    • 79952229913 scopus 로고    scopus 로고
    • Need for better diabetes treatment for improved renal outcome
    • P. Rossing, and D. de Zeeuw Need for better diabetes treatment for improved renal outcome Kidney Int Suppl 120 2011 S28 S32
    • (2011) Kidney Int Suppl , vol.120
    • Rossing, P.1    De Zeeuw, D.2
  • 3
    • 67349117682 scopus 로고    scopus 로고
    • Recent advances in pharmacotherapy for diabetic nephropathy: Current perspectives and future directions
    • P. Balakumar, M.K. Arora, S.S. Ganti, J. Reddy, and M. Singh Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions Pharmacol Res 60 2009 24 32
    • (2009) Pharmacol Res , vol.60 , pp. 24-32
    • Balakumar, P.1    Arora, M.K.2    Ganti, S.S.3    Reddy, J.4    Singh, M.5
  • 4
    • 73349120559 scopus 로고    scopus 로고
    • Do resident renal mast cells play a role in the pathogenesis of diabetic nephropathy?
    • P. Balakumar, J. Reddy, and M. Singh Do resident renal mast cells play a role in the pathogenesis of diabetic nephropathy? Mol Cell Biochem 330 2009 187 192
    • (2009) Mol Cell Biochem , vol.330 , pp. 187-192
    • Balakumar, P.1    Reddy, J.2    Singh, M.3
  • 5
    • 79958719334 scopus 로고    scopus 로고
    • The role of angiotension receptor blockers in diabetic nephropathy
    • A.M. Sharma, and M.R. Weir The role of angiotension receptor blockers in diabetic nephropathy Postgrad Med 123 2011 109 121
    • (2011) Postgrad Med , vol.123 , pp. 109-121
    • Sharma, A.M.1    Weir, M.R.2
  • 6
    • 79952191189 scopus 로고    scopus 로고
    • Do fibrates truly preserve kidney function?
    • S.M. Udani, and G.L. Bakris Do fibrates truly preserve kidney function? Nat Rev Endocrinol 7 2011 130 131
    • (2011) Nat Rev Endocrinol , vol.7 , pp. 130-131
    • Udani, S.M.1    Bakris, G.L.2
  • 7
    • 33748309114 scopus 로고    scopus 로고
    • Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74
    • DOI 10.2337/db05-1620
    • R. Retnakaran, C.A. Cull, K.I. Thorne, A.I. Alder, R.R. Holman UKPDS Study Group Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74 Diabetes 55 2006 1832 1839 (Pubitemid 44324140)
    • (2006) Diabetes , vol.55 , Issue.6 , pp. 1832-1839
    • Retnakaran, R.1    Cull, C.A.2    Thorne, K.I.3    Adler, A.I.4    Holman, R.R.5
  • 8
    • 77956636092 scopus 로고    scopus 로고
    • Role of triglyceride-rich lipoproteins in diabetic nephropathy
    • J.C. Rutledge, K.F. Ng, H.H. Aung, and D.W. Wilson Role of triglyceride-rich lipoproteins in diabetic nephropathy Nat Rev Nephrol 6 2010 361 370
    • (2010) Nat Rev Nephrol , vol.6 , pp. 361-370
    • Rutledge, J.C.1    Ng, K.F.2    Aung, H.H.3    Wilson, D.W.4
  • 10
    • 74249096576 scopus 로고    scopus 로고
    • Pathogenesis of diabetic nephropathy: Involvement of multifaceted signalling mechanism
    • P. Balakumar, M.K. Arora, J. Reddy, and M.B. Anand-Srivastava Pathogenesis of diabetic nephropathy: involvement of multifaceted signalling mechanism J Cardiovasc Pharmacol 54 2009 129 138
    • (2009) J Cardiovasc Pharmacol , vol.54 , pp. 129-138
    • Balakumar, P.1    Arora, M.K.2    Reddy, J.3    Anand-Srivastava, M.B.4
  • 11
    • 80052759436 scopus 로고    scopus 로고
    • Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats
    • V.P. Bilan, E.M. Salah, S. Bastacky, H.B. Jones, R.M. Mayers, and B. Zinker Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats J Endocrinol 210 2011 293 308
    • (2011) J Endocrinol , vol.210 , pp. 293-308
    • Bilan, V.P.1    Salah, E.M.2    Bastacky, S.3    Jones, H.B.4    Mayers, R.M.5    Zinker, B.6
  • 13
    • 34247609729 scopus 로고    scopus 로고
    • Glucosuria and albuminuria in diabetic nephropathy: A consideration at nanolevel
    • DOI 10.1016/j.jdiacomp.2005.11.001, PII S1056872705001510
    • V. Wiwanitkit Glucosuria and albuminuria in diabetic nephropathy: a consideration at nanolevel J Diabetes Complications 21 2007 164 165 (Pubitemid 46687065)
    • (2007) Journal of Diabetes and its Complications , vol.21 , Issue.3 , pp. 164-165
    • Wiwanitkit, V.1
  • 15
    • 77952674092 scopus 로고    scopus 로고
    • The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy
    • M.K. Arora, K. Reddy, and P. Balakumar The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy Eur J Pharmacol 636 2010 137 144
    • (2010) Eur J Pharmacol , vol.636 , pp. 137-144
    • Arora, M.K.1    Reddy, K.2    Balakumar, P.3
  • 16
    • 80052269271 scopus 로고    scopus 로고
    • Does microvascular disease predict macrovascular events in type 2 diabetes?
    • R.S. Rosenson, P. Fioretto, and P.M. Dodson Does microvascular disease predict macrovascular events in type 2 diabetes? Atherosclerosis 218 2011 13 18
    • (2011) Atherosclerosis , vol.218 , pp. 13-18
    • Rosenson, R.S.1    Fioretto, P.2    Dodson, P.M.3
  • 17
    • 23644438916 scopus 로고    scopus 로고
    • db/db mice with type 2 diabetes
    • DOI 10.2337/diabetes.54.8.2328
    • Z. Wang, T. Jiang, J. Li, G. Proctor, J.L. McManaman, and S. Lucia Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVB db/db mice with type 2 diabetes Diabetes 54 2005 2328 2335 (Pubitemid 41134259)
    • (2005) Diabetes , vol.54 , Issue.8 , pp. 2328-2335
    • Wang, Z.1    Jiang, T.2    Li, J.3    Proctor, G.4    McManaman, J.L.5    Lucia, S.6    Chua, S.7    Levi, M.8
  • 18
    • 67349188030 scopus 로고    scopus 로고
    • Emerging role of PPAR ligands in the management of diabetic nephropathy
    • P. Balakumar, M.K. Arora, and M. Singh Emerging role of PPAR ligands in the management of diabetic nephropathy Pharmacol Res 60 2009 170 173
    • (2009) Pharmacol Res , vol.60 , pp. 170-173
    • Balakumar, P.1    Arora, M.K.2    Singh, M.3
  • 19
    • 58049134293 scopus 로고    scopus 로고
    • Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat
    • P. Balakumar, V.A. Chakkarwar, and M. Singh Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat Mol Cell Biochem 320 2009 149 162
    • (2009) Mol Cell Biochem , vol.320 , pp. 149-162
    • Balakumar, P.1    Chakkarwar, V.A.2    Singh, M.3
  • 20
    • 77952688396 scopus 로고    scopus 로고
    • Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice
    • D. Taneja, J. Thompson, P. Wilson, K. Brandewie, L. Schaefer, and B. Mitchell Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice J Lipid Res 51 2010 1464 1470
    • (2010) J Lipid Res , vol.51 , pp. 1464-1470
    • Taneja, D.1    Thompson, J.2    Wilson, P.3    Brandewie, K.4    Schaefer, L.5    Mitchell, B.6
  • 21
    • 84858342274 scopus 로고    scopus 로고
    • Therapeutic target achievement in type 2 diabetic patients after hyperglycemia, hypertension, dyslipidemia management
    • A.Y. Kang, S.K. Park, S.Y. Park, H.J. Lee, Y. Han, and S.R. Lee Therapeutic target achievement in type 2 diabetic patients after hyperglycemia, hypertension, dyslipidemia management Diabetes Metab J 35 2011 264 272
    • (2011) Diabetes Metab J , vol.35 , pp. 264-272
    • Kang, A.Y.1    Park, S.K.2    Park, S.Y.3    Lee, H.J.4    Han, Y.5    Lee, S.R.6
  • 22
    • 0034951366 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease
    • DOI 10.1046/j.1523-1755.2001.00766.x
    • Y.F. Guan, and M.D. Breyer Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease Kidney Int 60 2001 14 30 (Pubitemid 32587535)
    • (2001) Kidney International , vol.60 , Issue.1 , pp. 14-30
    • Guan, Y.1    Breyer, M.D.2
  • 23
    • 35548942603 scopus 로고    scopus 로고
    • Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: The role of PPARα
    • DOI 10.3132/dvdr.2007.020
    • J. Plutzky Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPAR alpha Diab Vasc Dis Res 4 2007 S12 S14 (Pubitemid 350013472)
    • (2007) Diabetes and Vascular Disease Research , vol.4 , Issue.SUPPL. 3
    • Plutzky, J.1
  • 24
    • 64749088854 scopus 로고    scopus 로고
    • Fibrates and microvascular complications in diabetes - Insight from the FIELD study
    • J.C. Ansquer, C. Foucher, P. Aubonnet, and K. Le Malicot Fibrates and microvascular complications in diabetes - insight from the FIELD study Curr Pharm Des 15 2009 537 552
    • (2009) Curr Pharm des , vol.15 , pp. 537-552
    • Ansquer, J.C.1    Foucher, C.2    Aubonnet, P.3    Le Malicot, K.4
  • 25
    • 79952268700 scopus 로고    scopus 로고
    • Fenofibrate treatment enhances antioxidant status and attenuates endothelial dysfunction in streptozotocin-induced diabetic rats
    • M. Olukman, E.D. Sezer, S. Ulker, E.Y. Sözmen, and G.M. Cinar Fenofibrate treatment enhances antioxidant status and attenuates endothelial dysfunction in streptozotocin-induced diabetic rats Exp Diabetes Res 2010 2010 828531
    • (2010) Exp Diabetes Res , vol.2010 , pp. 828531
    • Olukman, M.1    Sezer, E.D.2    Ulker, S.3    Sözmen, E.Y.4    Cinar, G.M.5
  • 27
    • 70350700478 scopus 로고    scopus 로고
    • Transgenic expression of proximal tubule peroxisome proliferator- activated receptor-alpha in mice confers protection during acute kidney injury
    • S. Li, K.K. Nagothu, V. Desai, T. Lee, W. Branham, and C. Moland Transgenic expression of proximal tubule peroxisome proliferator-activated receptor-alpha in mice confers protection during acute kidney injury Kidney Int 76 2009 1049 1062
    • (2009) Kidney Int , vol.76 , pp. 1049-1062
    • Li, S.1    Nagothu, K.K.2    Desai, V.3    Lee, T.4    Branham, W.5    Moland, C.6
  • 28
    • 34548476007 scopus 로고    scopus 로고
    • Diabetic dyslipidemia and atherosclerosis: Evidence from clinical trials
    • DOI 10.1007/s11883-007-0013-8
    • J.A. Farmer Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials Curr Atheroscler Rep 9 2007 162 168 (Pubitemid 47376987)
    • (2007) Current Atherosclerosis Reports , vol.9 , Issue.2 , pp. 162-168
    • Farmer, J.A.1
  • 29
    • 77950626579 scopus 로고    scopus 로고
    • PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity
    • X. Hou, Y.H. Shen, C. Li, F. Wang, C. Zhang, and P. Bu PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity Biochem Biophys Res Commun 394 2010 653 659
    • (2010) Biochem Biophys Res Commun , vol.394 , pp. 653-659
    • Hou, X.1    Shen, Y.H.2    Li, C.3    Wang, F.4    Zhang, C.5    Bu, P.6
  • 30
    • 79959494229 scopus 로고    scopus 로고
    • Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus
    • C. Wanner, and V. Krane Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus Kidney Blood Press Res 34 2011 209 217
    • (2011) Kidney Blood Press Res , vol.34 , pp. 209-217
    • Wanner, C.1    Krane, V.2
  • 31
    • 33646508121 scopus 로고    scopus 로고
    • PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice
    • C.W. Park, Y. Zhang, X. Zhang, J. Wu, L. Chen, and D.R. Cha PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice Kidney Int 69 2006 1511 1517
    • (2006) Kidney Int , vol.69 , pp. 1511-1517
    • Park, C.W.1    Zhang, Y.2    Zhang, X.3    Wu, J.4    Chen, L.5    Cha, D.R.6
  • 32
    • 14844292088 scopus 로고    scopus 로고
    • Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)
    • DOI 10.1053/j.ajkd.2004.11.004
    • J.C. Ansquer, C. Foucher, S. Rattier, M.R. Taskinen, G. Steiner DAIS Investigators Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS) Am J Kidney Dis 45 2005 485 493 (Pubitemid 40341327)
    • (2005) American Journal of Kidney Diseases , vol.45 , Issue.3 , pp. 485-493
    • Ansquer, J.-C.1    Foucher, C.2    Rattier, S.3    Taskinen, M.-R.4    Steiner, G.5
  • 33
    • 78951474167 scopus 로고    scopus 로고
    • Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
    • T.M. Davis, R. Ting, J.D. Best, M.W. Donoghoe, P.L. Drury, and D.R. Sullivan Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Diabetologia 54 2011 280 290
    • (2011) Diabetologia , vol.54 , pp. 280-290
    • Davis, T.M.1    Ting, R.2    Best, J.D.3    Donoghoe, M.W.4    Drury, P.L.5    Sullivan, D.R.6
  • 34
    • 78650256519 scopus 로고    scopus 로고
    • Treatment of dyslipidemia in patients with type 2 diabetes
    • K. Vijayaraghavan Treatment of dyslipidemia in patients with type 2 diabetes Lipids Health Dis 9 2010 144
    • (2010) Lipids Health Dis , vol.9 , pp. 144
    • Vijayaraghavan, K.1
  • 35
    • 33748444602 scopus 로고    scopus 로고
    • Management of dyslipidemia in diabetes
    • DOI 10.1097/01.crd.0000188034.76283.5e, PII 0004541520060500000003
    • M.P. Solano, and R.B. Goldberg Management of dyslipidemia in diabetes Cardiol Rev 14 2006 125 135 (Pubitemid 44350383)
    • (2006) Cardiology in Review , vol.14 , Issue.3 , pp. 125-135
    • Solano, M.P.1    Goldberg, R.B.2
  • 37
    • 46249093117 scopus 로고    scopus 로고
    • Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome
    • M. Adiels, S.O. Olofsson, M.R. Taskinen, and J. Borén Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome Arterioscler Thromb Vasc Biol 28 2008 1225 1236
    • (2008) Arterioscler Thromb Vasc Biol , vol.28 , pp. 1225-1236
    • Adiels, M.1    Olofsson, S.O.2    Taskinen, M.R.3    Borén, J.4
  • 38
    • 0344034769 scopus 로고    scopus 로고
    • Lipoprotein abnormalities and their consequences for patients with type 2 diabetes
    • DOI 10.1046/j.1462-8902.2003.0310.x
    • A.J. Krentz Lipoprotein abnormalities and their consequences for patients with type 2 diabetes Diabetes Obes Metab 5 2003 S19 S27 (Pubitemid 37483614)
    • (2003) Diabetes, Obesity and Metabolism , vol.5 , Issue.SUPPL. 1
    • Krentz, A.J.1
  • 40
    • 0344739627 scopus 로고    scopus 로고
    • Role of lipases, lecithin: Cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin Resistace and type 2 diabetes mellitus
    • R. de Vries, S.E. Borggreve, and R.P. Dullaart Role of lipases, lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus Clin Lab 49 2003 601 613 (Pubitemid 37493458)
    • (2003) Clinical Laboratory , vol.49 , Issue.11-12 , pp. 601-613
    • De Vries, R.1    Borggreve, S.E.2    Dullaart, R.P.F.3
  • 41
    • 0346880515 scopus 로고    scopus 로고
    • Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: Role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins
    • DOI 10.1111/j.1365-2362.2003.01263.x
    • S.E. Borggreve, R. De Vries, and R.P. Dullaart Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins Eur J Clin Invest 33 2003 1051 1069 (Pubitemid 38019139)
    • (2003) European Journal of Clinical Investigation , vol.33 , Issue.12 , pp. 1051-1069
    • Borggreve, S.E.1    De Vries, R.2    Dullaart, R.P.F.3
  • 42
    • 42949116365 scopus 로고    scopus 로고
    • Lipid accumulation in non-adipose tissue and lipotoxicity
    • DOI 10.1016/j.physbeh.2007.11.049, PII S0031938407004805
    • N.A. van Herpen, and V.B. Schrauwen-Hinderling Lipid accumulation in non-adipose tissue and lipotoxicity Physiol Behav 94 2008 231 241 (Pubitemid 351615422)
    • (2008) Physiology and Behavior , vol.94 , Issue.2 , pp. 231-241
    • Van Herpen, N.A.1    Schrauwen-Hinderling, V.B.2
  • 43
    • 80052864426 scopus 로고    scopus 로고
    • Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy
    • J. Thompson, P. Wilson, K. Brandewie, D. Taneja, L. Schaefer, and B. Mitchell Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy Am J Pathol 179 2011 1179 1187
    • (2011) Am J Pathol , vol.179 , pp. 1179-1187
    • Thompson, J.1    Wilson, P.2    Brandewie, K.3    Taneja, D.4    Schaefer, L.5    Mitchell, B.6
  • 45
    • 14544298806 scopus 로고    scopus 로고
    • Cell surface heparan sulfate proteoglycans contribute to intracellular lipid accumulation in adipocytes
    • L.C. Wilsie, S. Chanchani, D. Navaratna, and R.A. Orlando Cell surface heparan sulfate proteoglycans contribute to intracellular lipid accumulation in adipocytes Lipids Health Dis 4 2005 2
    • (2005) Lipids Health Dis , vol.4 , pp. 2
    • Wilsie, L.C.1    Chanchani, S.2    Navaratna, D.3    Orlando, R.A.4
  • 46
    • 0026766973 scopus 로고
    • Heparan sulfate proteoglycans are lost in patients with diabetic nephropathy
    • H. Makino, S. Ikeda, T. Haramoto, and Z. Ota Heparan sulfate proteoglycans are lost in patients with diabetic nephropathy Nephron 61 1992 415 421
    • (1992) Nephron , vol.61 , pp. 415-421
    • Makino, H.1    Ikeda, S.2    Haramoto, T.3    Ota, Z.4
  • 48
    • 70349984006 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats
    • S.J. Shin, J.H. Lim, S. Chung, D.Y. Youn, H.W. Chung, and H.W. Kim Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats Hypertens Res 32 2009 835 845
    • (2009) Hypertens Res , vol.32 , pp. 835-845
    • Shin, S.J.1    Lim, J.H.2    Chung, S.3    Youn, D.Y.4    Chung, H.W.5    Kim, H.W.6
  • 49
    • 33745313224 scopus 로고    scopus 로고
    • Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha
    • C.W. Park, H.W. Kim, S.H. Ko, H.W. Chung, S.W. Lim, and C.W. Yang Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha Diabetes 55 2006 885 893
    • (2006) Diabetes , vol.55 , pp. 885-893
    • Park, C.W.1    Kim, H.W.2    Ko, S.H.3    Chung, H.W.4    Lim, S.W.5    Yang, C.W.6
  • 50
    • 1842295133 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors
    • J. DiRenzo, M. Söderstrom, R. Kurokawa, M.H. Ogliastro, M. Ricote, and S. Ingrey Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors Mol Cell Biol 17 1997 2166 2176 (Pubitemid 27133303)
    • (1997) Molecular and Cellular Biology , vol.17 , Issue.4 , pp. 2166-2176
    • Direnzo, J.1    Soderstrom, M.2    Kurokawa, R.3    Ogliastro, M.-H.4    Ricote, M.5    Ingrey, S.6    Horlein, A.7    Rosenfeld, M.G.8    Glass, C.K.9
  • 52
    • 78349283454 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor alpha target genes
    • pii:612089
    • M. Rakhshandehroo, B. Knoch, M. Müller, and S. Kersten Peroxisome proliferator-activated receptor alpha target genes PPAR Res 201 2010 0 pii:612089
    • (2010) PPAR Res , vol.201 , pp. 0
    • Rakhshandehroo, M.1    Knoch, B.2    Müller, M.3    Kersten, S.4
  • 53
    • 77957189397 scopus 로고    scopus 로고
    • Protection against nephropathy with fenofibrate in type 2 diabetes mellitus: The FIELD study
    • A. Keech, P. Drury, T.M. Davis, M. Donoghoe, M. Laakso, and M. Whiting Protection against nephropathy with fenofibrate in type 2 diabetes mellitus: the FIELD study Circulation 120 2009 S419 S420
    • (2009) Circulation , vol.120
    • Keech, A.1    Drury, P.2    Davis, T.M.3    Donoghoe, M.4    Laakso, M.5    Whiting, M.6
  • 54
    • 78650796942 scopus 로고    scopus 로고
    • Role of PPARα and its agonist in renal diseases
    • C.F. Cheng, H.H. Chen, and H. Lin Role of PPARα and its agonist in renal diseases PPAR Res 2010 2010 345098
    • (2010) PPAR Res , vol.2010 , pp. 345098
    • Cheng, C.F.1    Chen, H.H.2    Lin, H.3
  • 55
    • 0029900979 scopus 로고    scopus 로고
    • Lipids and progressive renal failure
    • W.F. Keane Lipids and progressive renal failure Wien Klin Wochenschr 108 1996 420 424 (Pubitemid 26253643)
    • (1996) Wiener Klinische Wochenschrift , vol.108 , Issue.14 , pp. 420-424
    • Keane, W.F.1
  • 56
    • 0034034681 scopus 로고    scopus 로고
    • The role of lipids in renal disease: Future challenges
    • W.F. Keane The role of lipids in renal disease: future challenges Kidney Int Suppl 75 2000 S27 S31 (Pubitemid 30205436)
    • (2000) Kidney International, Supplement , vol.57 , Issue.75
    • Keane, W.F.1
  • 57
    • 0029655754 scopus 로고    scopus 로고
    • Effects of Lipids on the Pathogenesis of Progressive Renal Failure: Role of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in the Prevention of Glomerulosclerosis
    • C. Guijarro, and W.F. Keane Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis Miner Electrolyte Metab 22 1996 147 152 (Pubitemid 126448826)
    • (1996) Mineral and Electrolyte Metabolism , vol.22 , Issue.1-3 , pp. 147-152
    • Guijarro, C.1    Keane, W.F.2
  • 58
    • 61349119943 scopus 로고    scopus 로고
    • Vascular endothelial dysfunction: A tug of war in diabetic nephropathy?
    • P. Balakumar, V.A. Chakkarwar, P. Krishan, and M. Singh Vascular endothelial dysfunction: a tug of war in diabetic nephropathy? Biomed Pharmacother 63 2009 171 179
    • (2009) Biomed Pharmacother , vol.63 , pp. 171-179
    • Balakumar, P.1    Chakkarwar, V.A.2    Krishan, P.3    Singh, M.4
  • 59
    • 80052681811 scopus 로고    scopus 로고
    • Involvement of MAPKs in ICAM-1 expression in glomerular endothelial cells in diabetic nephropathy
    • N. Watanabe, K. Shikata, Y. Shikata, K. Sarai, K. Omori, and R. Kodera Involvement of MAPKs in ICAM-1 expression in glomerular endothelial cells in diabetic nephropathy Acta Med Okayama 65 2011 247 257
    • (2011) Acta Med Okayama , vol.65 , pp. 247-257
    • Watanabe, N.1    Shikata, K.2    Shikata, Y.3    Sarai, K.4    Omori, K.5    Kodera, R.6
  • 60
    • 84855181132 scopus 로고    scopus 로고
    • Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes?
    • J. Jankun, A. Al-Senaidy, and E. Skzypczak-Jankun Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? Int J Mol Med 29 2012 3 11
    • (2012) Int J Mol Med , vol.29 , pp. 3-11
    • Jankun, J.1    Al-Senaidy, A.2    Skzypczak-Jankun, E.3
  • 61
    • 46449103466 scopus 로고    scopus 로고
    • Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats
    • L. Chen, J. Zhang, Y. Zhang, Y. Wang, and B. Wang Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats Inflamm Res 57 2008 199 204
    • (2008) Inflamm Res , vol.57 , pp. 199-204
    • Chen, L.1    Zhang, J.2    Zhang, Y.3    Wang, Y.4    Wang, B.5
  • 62
    • 33646156170 scopus 로고    scopus 로고
    • Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1
    • L.L. Chen, J.Y. Zhang, and B.P. Wang Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1 Vascul Pharmacol 44 2006 309 315
    • (2006) Vascul Pharmacol , vol.44 , pp. 309-315
    • Chen, L.L.1    Zhang, J.Y.2    Wang, B.P.3
  • 63
    • 84925939424 scopus 로고    scopus 로고
    • Transforming growth factor-β and Smads
    • H.Y. Lan, and A.C. Chung Transforming growth factor-β and Smads Contrib Nephrol 170 2011 75 82
    • (2011) Contrib Nephrol , vol.170 , pp. 75-82
    • Lan, H.Y.1    Chung, A.C.2
  • 64
    • 80052316668 scopus 로고    scopus 로고
    • Smad3-mediated upregulation of miR-21 promotes renal fibrosis
    • X. Zhong, A.C. Chung, H.Y. Chen, X.M. Meng, and H.Y. Lan Smad3-mediated upregulation of miR-21 promotes renal fibrosis J Am Soc Nephrol 22 2011 1668 1681
    • (2011) J Am Soc Nephrol , vol.22 , pp. 1668-1681
    • Zhong, X.1    Chung, A.C.2    Chen, H.Y.3    Meng, X.M.4    Lan, H.Y.5
  • 65
    • 77950229811 scopus 로고    scopus 로고
    • Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy
    • L. Li, N. Emmett, D. Mann, and X. Zhao Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy Exp Biol Med (Maywood) 235 2010 383 391
    • (2010) Exp Biol Med (Maywood) , vol.235 , pp. 383-391
    • Li, L.1    Emmett, N.2    Mann, D.3    Zhao, X.4
  • 66
    • 84858343166 scopus 로고    scopus 로고
    • High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARα-FoxO3a-PGC-1α pathway
    • 10.1093/ndt/gfr613
    • H.W. Chung, J.H. Lim, M.Y. Kim, S.J. Shin, S. Chung, and B.S. Choi High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARα-FoxO3a-PGC-1α pathway Nephrol Dial Transplant 2011 10.1093/ndt/gfr613
    • (2011) Nephrol Dial Transplant
    • Chung, H.W.1    Lim, J.H.2    Kim, M.Y.3    Shin, S.J.4    Chung, S.5    Choi, B.S.6
  • 67
    • 79953240855 scopus 로고    scopus 로고
    • Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis
    • Y. Tanaka, S. Kume, S. Araki, K. Isshiki, M. Chin-Kanasaki, and M. Sakaguchi Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis Kidney Int 79 2011 871 882
    • (2011) Kidney Int , vol.79 , pp. 871-882
    • Tanaka, Y.1    Kume, S.2    Araki, S.3    Isshiki, K.4    Chin-Kanasaki, M.5    Sakaguchi, M.6
  • 70
    • 35848956112 scopus 로고    scopus 로고
    • Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production
    • DOI 10.1681/ASN.2006080895
    • S. Prabhakar, J. Starnes, S. Shi, B. Lonis, and R. Tran Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production J Am Soc Nephrol 18 2007 2945 2952 (Pubitemid 350058402)
    • (2007) Journal of the American Society of Nephrology , vol.18 , Issue.11 , pp. 2945-2952
    • Prabhakar, S.1    Starnes, J.2    Shi, S.3    Lonis, B.4    Tran, R.5
  • 71
    • 79952986434 scopus 로고    scopus 로고
    • Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation
    • A. Tomizawa, Y. Hattori, T. Inoue, S. Hattori, and K. Kasai Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation Metabolism 60 2011 513 522
    • (2011) Metabolism , vol.60 , pp. 513-522
    • Tomizawa, A.1    Hattori, Y.2    Inoue, T.3    Hattori, S.4    Kasai, K.5
  • 72
    • 61649091558 scopus 로고    scopus 로고
    • Fenofibrate monotherapy-induced rhabdomyolysis in a patient with type-2 diabetes
    • R. Cetinkaya, A. Uyanik, R. Yildirim, Y. Bilen, and M. Keles Fenofibrate monotherapy-induced rhabdomyolysis in a patient with type-2 diabetes Indian J Med Sci 62 2008 458 459
    • (2008) Indian J Med Sci , vol.62 , pp. 458-459
    • Cetinkaya, R.1    Uyanik, A.2    Yildirim, R.3    Bilen, Y.4    Keles, M.5
  • 73
    • 71349086893 scopus 로고    scopus 로고
    • Rhabdomyolysis associated with fibrate therapy: Review of 76 published cases and a new case report
    • J. Wu, Y. Song, H. Li, and J. Chen Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report Eur J Clin Pharmacol 65 2009 1169 1174
    • (2009) Eur J Clin Pharmacol , vol.65 , pp. 1169-1174
    • Wu, J.1    Song, Y.2    Li, H.3    Chen, J.4
  • 74
    • 34548182594 scopus 로고    scopus 로고
    • PPAR dual agonists: Are they opening Pandora's Box?
    • DOI 10.1016/j.phrs.2007.03.002, PII S1043661807000503
    • P. Balakumar, M. Rose, S.S. Ganti, P. Krishan, and M. Singh PPAR dual agonists: are they opening Pandora's Box? Pharmacol Res 56 2007 91 98 (Pubitemid 47304493)
    • (2007) Pharmacological Research , vol.56 , Issue.2 , pp. 91-98
    • Balakumar, P.1    Rose, M.2    Ganti, S.S.3    Krishan, P.4    Singh, M.5
  • 75
    • 35548979848 scopus 로고    scopus 로고
    • The role of fenofibrate in clinical practice
    • DOI 10.3132/dvdr.2007.053
    • A. Zambon, and K. Cusi The role of fenofibrate in clinical practice Diab Vasc Dis Res 4 2007 S15 S20 (Pubitemid 350013473)
    • (2007) Diabetes and Vascular Disease Research , vol.4 , Issue.SUPPL. 3
    • Zambon, A.1    Cusi, K.2
  • 76
    • 0036364909 scopus 로고    scopus 로고
    • Fenofibrate increases creatininemia by increasing metabolic production of creatinine
    • C. Hottelart, N. El Esper, F. Rose, J.M. Achard, and A. Fournier Fenofibrate increases creatininemia by increasing metabolic production of creatinine Nephron 92 2002 536 541
    • (2002) Nephron , vol.92 , pp. 536-541
    • Hottelart, C.1    El Esper, N.2    Rose, F.3    Achard, J.M.4    Fournier, A.5
  • 78
    • 0034575092 scopus 로고    scopus 로고
    • Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients
    • T. Nagai, T. Tomizawa, K. Nakajima, and M. Mori Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients J Atheroscler Thromb 7 2000 91 96
    • (2000) J Atheroscler Thromb , vol.7 , pp. 91-96
    • Nagai, T.1    Tomizawa, T.2    Nakajima, K.3    Mori, M.4
  • 79
    • 83755220049 scopus 로고    scopus 로고
    • Interplay between statins and PPARs in improving cardiovascular outcomes: A double-edged sword?
    • P. Balakumar, and N. Mahadevan Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword? Br J Pharmacol 165 2012 373 379
    • (2012) Br J Pharmacol , vol.165 , pp. 373-379
    • Balakumar, P.1    Mahadevan, N.2
  • 80
    • 84155180948 scopus 로고    scopus 로고
    • Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?
    • P. Balakumar, S. Kathuria, G. Taneja, S. Kalra, and N. Mahadevan Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins? J Mol Cell Cardiol 52 2012 83 92
    • (2012) J Mol Cell Cardiol , vol.52 , pp. 83-92
    • Balakumar, P.1    Kathuria, S.2    Taneja, G.3    Kalra, S.4    Mahadevan, N.5
  • 81
    • 38349018842 scopus 로고    scopus 로고
    • Elevated serum creatinine levels associated with fenofibrate therapy
    • C.R. McQuade, J. Griego, J. Anderson, and A.B. Pai Elevated serum creatinine levels associated with fenofibrate therapy Am J Health Syst Pharm 65 2008 138 141
    • (2008) Am J Health Syst Pharm , vol.65 , pp. 138-141
    • McQuade, C.R.1    Griego, J.2    Anderson, J.3    Pai, A.B.4
  • 82
    • 33645661252 scopus 로고    scopus 로고
    • Fenofibrate can increase serum creatinine levels in renal insufficiency
    • S. Paul, and V. Mohan Fenofibrate can increase serum creatinine levels in renal insufficiency J Assoc Physicians India 54 2006 337 (Pubitemid 43528618)
    • (2006) Journal of Association of Physicians of India , vol.54 , Issue.APR. , pp. 337
    • Paul, S.1    Mohan, V.2
  • 83
    • 0032617597 scopus 로고    scopus 로고
    • Le fenofibrate augmente la creatininemie mais n'altere pas le debit de filtration glomerulaire chez les patients presentant une insuffisance renale moderee
    • C. Hottelart, N. el Esper, J.M. Achard, A. Pruna, and A. Fournier Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency Nephrologie 20 1999 41 44 (Pubitemid 29091030)
    • (1999) Nephrologie , vol.20 , Issue.1 , pp. 41-44
    • Hottelart, C.1    El Esper, N.2    Achard, J.-M.3    Pruna, A.4    Fournier, A.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.